Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the primary endpoint in an MDD trial, azetukalner's potential in epilepsy remains strong, with long-term data showing sustained seizure reduction. Financially, Xenon Pharma has a solid cash position, providing a runway of 11–13 quarters, making it an attractive investment at current low prices.
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Douglas Tsao - H.C. Wainwright Operator Hello and thank you for standing by.
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time.
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Caroline Pocher - JPMorgan Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Luke Herrmann - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Paul Choi - Goldman Sachs Danielle Brill - Raymond James Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Dylan Shindler - Wedbush Securities Operator Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call.
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript
Xenon Pharmaceuticals, Inc. (NASDAQ:XENE ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Chad Fugere - VP, IR Ian Mortimer - President & CEO Chris Kenney - CMO Sherry Aulin - CFO Chris Von Seggern - CCO Conference Call Participants Paul Matteis - Stifel Leo Leung - RBC Capital Markets Tessa Romero - J.P. Morgan Dina Ramadane - Bank of America Luke Herrmann - Baird Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Peyton Bohnsack - TD Cowen Dylan Shindler - Wedbush Securities Basma Radwan - Leerink Partners Operator Thank you for standing by.
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
